{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T04:47:09Z","timestamp":1783226829415,"version":"3.54.6"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Preclinical and clinical data indicate that the 5-lipoxygenase pathway becomes activated in cardiovascular diseases suggesting an important role of CysLTs in atherosclerosis and in its ischemic complications. This study aims to investigate the effects of montelukast, a CysLTR-1 antagonist, in a mouse model of myocardial infarction (MI). C57BL\/6N female mice were subjected to coronary artery ligation and received montelukast (10\u00a0mg\/kg\/day, intraperitoneal) or vehicle. Montelukast exerted beneficial effects in the infarcted area, decreasing mRNA expression of inflammatory genes, such Il1\u03b2 and Ccl2 (p\u2009&lt;\u20090.05), at 48\u00a0h after MI, and reducing infarct size and preventing ischemic wall thinning (p\u2009&lt;\u20090.05) at 4\u00a0weeks. Furthermore, montelukast counteracted maladaptive remodelling of whole heart. Indeed, montelukast reduced LV mass (p\u2009&lt;\u20090.05) and remote wall thickening (p\u2009&lt;\u20090.05), and improved cardiac pumping function, as evidenced by increased global ejection fraction (p\u2009&lt;\u20090.01), and regional contractility in infarcted (p\u2009&lt;\u20090.05) and in remote non-infarcted (p\u2009&lt;\u20090.05) myocardium. Finally, montelukast prevented cardiomyocytes hypertrophy (p\u2009&lt;\u20090.05) in remote myocardium, reducing the phosphorylation of GSK3\u03b2, a regulator of hypertrophic pathway (p\u2009&lt;\u20090.05). Our data strongly demonstrate the ability of montelukast to contrast the MI-induced maladaptive conditions, thus sustaining cardiac contractility. The results provide evidences for montelukast \u201crepurposing\u201d in cardiovascular diseases and in particular in myocardial infarction.<\/jats:p>","DOI":"10.1038\/s41598-024-53936-x","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:02:25Z","timestamp":1707476545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction"],"prefix":"10.1038","volume":"14","author":[{"given":"Majeda","family":"Muluhie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castiglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Rzemieniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Mercuriali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gelosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Sironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"53936_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"53936_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","volume":"24","author":"P Polamreddy","year":"2019","unstructured":"Polamreddy, P. & Gattu, N. The drug repurposing landscape from 2012 to 2017: Evolution, challenges, and possible solutions. Drug Discov. Today 24, 789\u2013795 (2019).","journal-title":"Drug Discov. Today"},{"key":"53936_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10557-008-6140-9","volume":"23","author":"M B\u00e4ck","year":"2009","unstructured":"B\u00e4ck, M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs Ther. 23, 41\u201348 (2009).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"53936_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/cvr\/cvq016","volume":"86","author":"D Poeckel","year":"2010","unstructured":"Poeckel, D. & Funk, C. D. The 5-lipoxygenase\/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc. Res. 86, 243\u2013253 (2010).","journal-title":"Cardiovasc. Res."},{"key":"53936_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/med.21251","volume":"33","author":"V Capra","year":"2013","unstructured":"Capra, V. et al. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med. Res. Rev. 33, 364\u2013438 (2013).","journal-title":"Med. Res. Rev."},{"key":"53936_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbrc.2017.02.125","volume":"486","author":"X Di","year":"2017","unstructured":"Di, X., Tang, X. & Di, X. Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclerosis. Biochem. Biophys. Res. Commun. 486, 58\u201362 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"53936_CR7","first-page":"633","volume":"59","author":"J Jawien","year":"2008","unstructured":"Jawien, J. et al. The effect of montelukast on atherogenesis in apoE\/LDLR-double knockout mice. J. Physiol. Pharmacol. 59, 633\u2013639 (2008).","journal-title":"J. Physiol. Pharmacol."},{"key":"53936_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.atherosclerosis.2008.11.012","volume":"205","author":"S Ge","year":"2009","unstructured":"Ge, S. et al. Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis 205, 74\u201379 (2009).","journal-title":"Atherosclerosis"},{"key":"53936_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10557-009-6211-6","volume":"23","author":"D Liu","year":"2009","unstructured":"Liu, D. et al. Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits. Cardiovasc. drugs Ther. 23, 431\u2013437 (2009).","journal-title":"Cardiovasc. drugs Ther."},{"key":"53936_CR10","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1073\/pnas.1717906115","volume":"115","author":"A Di Gennaro","year":"2018","unstructured":"Di Gennaro, A. et al. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm. Proc. Natl. Acad. Sci. USA 115, 1907\u20131912 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53936_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00109-012-0904-1","volume":"90","author":"A Eaton","year":"2012","unstructured":"Eaton, A., Nagy, E., Pacault, M., Fauconnier, J. & B\u00e4ck, M. Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression. J. Mol. Med. (Berl) 90, 1223\u20131231 (2012).","journal-title":"J. Mol. Med. (Berl)"},{"key":"53936_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10787-019-00611-7","volume":"27","author":"L Zhou","year":"2019","unstructured":"Zhou, L. et al. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier. Inflammopharmacology 27, 933\u2013940 (2019).","journal-title":"Inflammopharmacology"},{"key":"53936_CR13","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1038\/sj.emboj.7601341","volume":"25","author":"P Ciana","year":"2006","unstructured":"Ciana, P. et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides\/cysteinyl-leukotrienes receptor. EMBO J. 25, 4615\u20134627 (2006).","journal-title":"EMBO J."},{"key":"53936_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.phrs.2019.02.025","volume":"142","author":"P Gelosa","year":"2019","unstructured":"Gelosa, P. et al. Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug. Pharmacol. Res. 142, 223\u2013236 (2019).","journal-title":"Pharmacol. Res."},{"key":"53936_CR15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaci.2011.11.052","volume":"129","author":"E Ingelsson","year":"2012","unstructured":"Ingelsson, E., Yin, L. & B\u00e4ck, M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J. Allergy Clin. Immunol. 129, 702\u2013707 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"53936_CR16","doi-asserted-by":"publisher","first-page":"611561","DOI":"10.3389\/fphar.2020.611561","volume":"11","author":"M Hoxha","year":"2021","unstructured":"Hoxha, M. et al. Montelukast use decreases cardiovascular events in asthmatics. Front. Pharmacol. 11, 611561 (2021).","journal-title":"Front. Pharmacol."},{"key":"53936_CR17","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1378\/chest.07-0831","volume":"132","author":"H Allayee","year":"2007","unstructured":"Allayee, H. et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 132, 868\u2013874 (2007).","journal-title":"Chest"},{"key":"53936_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0041786","volume":"7","author":"E Nobili","year":"2012","unstructured":"Nobili, E. et al. Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. PLoS One 7, 1\u20139 (2012).","journal-title":"PLoS One"},{"key":"53936_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.yjmcc.2010.11.013","volume":"50","author":"UM Becher","year":"2011","unstructured":"Becher, U. M. et al. Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury. J. Mol. Cell. Cardiol. 50, 570\u2013577 (2011).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"53936_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0960327115591372","volume":"35","author":"A Khodir","year":"2016","unstructured":"Khodir, A., Ghoneim, H., Rahim, M. & Suddek, G. Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats. Hum. Exp. Toxicol. 35, 388\u2013397 (2016).","journal-title":"Hum. Exp. Toxicol."},{"key":"53936_CR21","doi-asserted-by":"crossref","unstructured":"Hemmati, A. A. et al. The evaluation of the ameliorative effect of montelukast against arsenic trioxide-induced cardiotoxicity in rats. Jundishapur J. Nat. Pharm. Prod. 12, e65046 (2017).","DOI":"10.5812\/jjnpp.65046"},{"key":"53936_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174892","volume":"923","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ. Eur. J. Pharmacol. 923, 174892 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"53936_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/2432958","volume":"2017","author":"F Colazzo","year":"2017","unstructured":"Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L. & Castiglioni, L. Role of the cysteinyl leukotrienes in the pathogenesis and progression of cardiovascular diseases. Mediators Inflamm. 2017, 1\u201313 (2017).","journal-title":"Mediators Inflamm."},{"key":"53936_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/01480545.2020.1730885","volume":"45","author":"HM Hafez","year":"2022","unstructured":"Hafez, H. M. & Hassanein, H. Montelukast ameliorates doxorubicin-induced cardiotoxicity via modulation of p-glycoprotein and inhibition of ROS-mediated TNF-\u03b1\/NF-\u03baB pathways. Drug Chem. Toxicol. 45, 548\u2013559 (2022).","journal-title":"Drug Chem. Toxicol."},{"key":"53936_CR25","doi-asserted-by":"publisher","first-page":"H375","DOI":"10.1152\/ajpheart.00498.2007","volume":"297","author":"GE Gonz\u00e1lez","year":"2009","unstructured":"Gonz\u00e1lez, G. E. et al. Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. Am. J. Physiol. Heart Circ. Physiol. 297, H375\u2013H386 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"53936_CR26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/01.RES.0000130526.20854.fa","volume":"94","author":"M Nian","year":"2004","unstructured":"Nian, M., Lee, P., Khaper, N. & Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94, 1543\u20131553 (2004).","journal-title":"Circ. Res."},{"key":"53936_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.hfc.2011.08.010","volume":"8","author":"A Abbate","year":"2012","unstructured":"Abbate, A. & Narula, J. Role of apoptosis in adverse ventricular remodeling. Heart Fail. Clin. 8, 79\u201386 (2012).","journal-title":"Heart Fail. Clin."},{"key":"53936_CR28","doi-asserted-by":"publisher","first-page":"H1303","DOI":"10.1152\/ajpheart.00053.2004","volume":"287","author":"D Engel","year":"2004","unstructured":"Engel, D., Peshock, R., Armstong, R. C., Sivasubramanian, N. & Mann, D. L. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am. J. Physiol. Circ. Physiol. 287, H1303\u2013H1311 (2004).","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"53936_CR29","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1172\/JCI32490","volume":"117","author":"A Diwan","year":"2007","unstructured":"Diwan, A. et al. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J. Clin. Invest. 117, 2825\u20132833 (2007).","journal-title":"J. Clin. Invest."},{"key":"53936_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.plefa.2010.01.003","volume":"83","author":"A Muthuraman","year":"2010","unstructured":"Muthuraman, A. & Sood, S. Antisecretory, antioxidative and antiapoptotic effects of montelukast on pyloric ligation and water immersion stress induced peptic ulcer in rat. Prostaglandins. Leukot. Essent. Fatty Acids 83, 55\u201360 (2010).","journal-title":"Prostaglandins. Leukot. Essent. Fatty Acids"},{"key":"53936_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.prostaglandins.2012.09.002","volume":"99","author":"M Ersahin","year":"2012","unstructured":"Ersahin, M. et al. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury. Prostaglandins Other Lipid Mediat. 99, 131\u2013139 (2012).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"53936_CR32","doi-asserted-by":"publisher","first-page":"9396425","DOI":"10.1155\/2017\/9396425","volume":"2017","author":"NA El-Boghdady","year":"2017","unstructured":"El-Boghdady, N. A., Abdeltawab, N. F. & Nooh, M. M. Resveratrol and montelukast alleviate paraquat-induced hepatic injury in mice: Modulation of oxidative stress, inflammation, and apoptosis. Oxid. Med. Cell. Longev. 2017, 9396425 (2017).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"53936_CR33","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.fertnstert.2010.08.017","volume":"95","author":"A Oral","year":"2011","unstructured":"Oral, A. et al. Protective effects of montelukast on ischemia-reperfusion injury in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation. Fertil. Steril. 95, 1360\u20131366 (2011).","journal-title":"Fertil. Steril."},{"key":"53936_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.phrs.2006.02.007","volume":"54","author":"G Sener","year":"2006","unstructured":"Sener, G. et al. Montelukast protects against renal ischemia\/reperfusion injury in rats. Pharmacol. Res. 54, 65\u201371 (2006).","journal-title":"Pharmacol. Res."},{"key":"53936_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000081072","volume":"73","author":"GL Yu","year":"2005","unstructured":"Yu, G. L. et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73, 31\u201340 (2005).","journal-title":"Pharmacology"},{"key":"53936_CR36","first-page":"757","volume":"25","author":"K Korkmaz","year":"2015","unstructured":"Korkmaz, K. et al. Effect of montelukast on spinal cord ischemia- reperfusion injury. Turk. Neurosurg. 25, 757\u2013765 (2015).","journal-title":"Turk. Neurosurg."},{"key":"53936_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jss.2008.07.031","volume":"157","author":"K Gideroglu","year":"2009","unstructured":"Gideroglu, K. et al. Montelukast protects axial pattern rat skin flaps against ischemia\/reperfusion injury. J. Surg. Res. 157, 181\u2013186 (2009).","journal-title":"J. Surg. Res."},{"key":"53936_CR38","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","volume":"117","author":"A Abbate","year":"2008","unstructured":"Abbate, A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670\u20132683 (2008).","journal-title":"Circulation"},{"key":"53936_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2353\/ajpath.2008.070974","volume":"173","author":"M Bujak","year":"2008","unstructured":"Bujak, M. et al. Interleukin-1 receptor type i signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 173, 57\u201367 (2008).","journal-title":"Am. J. Pathol."},{"key":"53936_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1113\/expphysiol.2012.069831","volume":"98","author":"S Toldo","year":"2013","unstructured":"Toldo, S. et al. Interleukin-1\u03b2 blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp. Physiol. 98, 734\u2013745 (2013).","journal-title":"Exp. Physiol."},{"key":"53936_CR41","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1161\/CIRCULATIONAHA.115.016160","volume":"132","author":"HB Sager","year":"2015","unstructured":"Sager, H. B. et al. Targeting interleukin-1\u03b2 reduces leukocyte production after acute myocardial infarction. Circulation 132, 1880\u20131890 (2015).","journal-title":"Circulation"},{"key":"53936_CR42","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.7150\/thno.31073","volume":"9","author":"N Wang","year":"2019","unstructured":"Wang, N. et al. Hyaluronic acid oligosaccharides improve myocardial function reconstruction and angiogenesis against myocardial infarction by regulation of macrophages. Theranostics 9, 1980\u20131992 (2019).","journal-title":"Theranostics"},{"key":"53936_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","volume":"119","author":"SD Prabhu","year":"2016","unstructured":"Prabhu, S. D. & Frangogiannis, N. G. The biological basis for cardiac repair after myocardial infarction. Circ. Res. 119, 91\u2013112 (2016).","journal-title":"Circ. Res."},{"key":"53936_CR44","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.7150\/thno.37106","volume":"10","author":"J Li","year":"2020","unstructured":"Li, J. et al. CD226 deletion improves post-infarction healing via modulating macrophage polarization in mice. Theranostics 10, 2422\u20132435 (2020).","journal-title":"Theranostics"},{"key":"53936_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1161\/01.RES.0000018952.70505.F1","volume":"90","author":"SE Hardt","year":"2002","unstructured":"Hardt, S. E. & Sadoshima, J. Glycogen synthase kinase-3beta: A novel regulator of cardiac hypertrophy and development. Circ. Res. 90, 1055\u20131063 (2002).","journal-title":"Circ. Res."},{"issue":"Suppl","key":"53936_CR46","first-page":"S137","volume":"153","author":"PH Sugden","year":"2008","unstructured":"Sugden, P. H., Fuller, S. J., Weiss, S. C. & Clerk, A. Glycogen synthase kinase 3 (GSK3) in the heart: A point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br. J. Pharmacol. 153(Suppl), S137\u2013S153 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"53936_CR47","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCRESAHA.116.303613","volume":"116","author":"H Lal","year":"2015","unstructured":"Lal, H., Ahmad, F., Woodgett, J. & Force, T. The GSK-3 family as therapeutic target for myocardial diseases. Circ. Res. 116, 138\u2013149 (2015).","journal-title":"Circ. Res."},{"key":"53936_CR48","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCRESAHA.109.211482","volume":"106","author":"KC Woulfe","year":"2010","unstructured":"Woulfe, K. C. et al. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ. Res. 106, 1635\u20131645 (2010).","journal-title":"Circ. Res."},{"key":"53936_CR49","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCRESAHA.111.249532","volume":"109","author":"P Zhai","year":"2011","unstructured":"Zhai, P., Sciarretta, S., Galeotti, J., Volpe, M. & Sadoshima, J. Differential roles of GSK-3\u03b2 during myocardial ischemia and ischemia\/reperfusion. Circ. Res. 109, 502\u2013511 (2011).","journal-title":"Circ. Res."},{"key":"53936_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135778","volume":"10","author":"L Castiglioni","year":"2015","unstructured":"Castiglioni, L. et al. Evaluation of left ventricle function by regional fractional area change (RFAC) in a Mouse model of myocardial infarction secondary to valsartan treatment. PLoS One 10, e0135778 (2015).","journal-title":"PLoS One"},{"key":"53936_CR51","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1038\/ncomms9466","volume":"6","author":"J Marschallinger","year":"2015","unstructured":"Marschallinger, J. et al. Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nat. Commun. 6, 8466 (2015).","journal-title":"Nat. Commun."},{"key":"53936_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.compbiomed.2011.06.021","volume":"41","author":"M Franzosi","year":"2011","unstructured":"Franzosi, M. et al. Feasibility of quantitative analysis of regional left ventricular function in the post-infarct mouse by magnetic resonance imaging with retrospective gating. Comput. Biol. Med. 41, 829\u2013837 (2011).","journal-title":"Comput. Biol. Med."},{"key":"53936_CR53","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1073\/pnas.0706315105","volume":"105","author":"J Tillmanns","year":"2008","unstructured":"Tillmanns, J. et al. Formation of large coronary arteries by cardiac progenitor cells. Proc. Natl. Acad. Sci. 105, 1668\u20131673 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"53936_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9051084","volume":"9","author":"L Sandrini","year":"2020","unstructured":"Sandrini, L. et al. Impact of BDNF Val66Met polymorphism on myocardial infarction: Exploring the macrophage phenotype. Cells 9, 1 (2020).","journal-title":"Cells"},{"key":"53936_CR55","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.ajpath.2020.05.010","volume":"190","author":"P Cassaglia","year":"2020","unstructured":"Cassaglia, P. et al. Genetic deletion of galectin-3 alters the temporal evolution of macrophage infiltration and healing affecting the cardiac remodeling and function after myocardial infarction in mice. Am. J. Pathol. 190, 1789\u20131800 (2020).","journal-title":"Am. J. Pathol."},{"key":"53936_CR56","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/HJH.0000000000001651","volume":"36","author":"L Castiglioni","year":"2018","unstructured":"Castiglioni, L. et al. Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. J. Hypertens. 36, 1129\u20131146 (2018).","journal-title":"J. Hypertens."},{"key":"53936_CR57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"M Bradford","year":"1976","unstructured":"Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248\u2013254 (1976).","journal-title":"Anal. Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53936-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53936-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53936-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T14:05:58Z","timestamp":1707746758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-53936-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-53936-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]},"assertion":[{"value":"2 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3371"}}